Induction of both cellular and humoral immunity following a rational prime-boost immunization regimen that incorporates recombinant ovine atadenovirus and fowlpox virus

Clinical and Vaccine Immunology

Volumn 17, Issue 11, 2010, Pages 1679-1686

  Fraser, Cara K ^a,f   Diener, Kerrilyn R ^a,f   Lousberg, Erin L ^a,f   Both, Gerald W ^b,g   Ward, Larry ^c   Brown, Michael P ^a,d,e   Hayball, John D ^a,e,f  

^a HANSON INSTITUTE   (Australia)

^b CSIRO   (Australia)

^c Virax Holdings Ltd   (Australia)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

^e UNIVERSITY OF ADELAIDE   (Australia)

^f UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^g Riverside Life Sciences Building   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATADENOVIRUS VECTOR; FOWLPOX VIRUS VECTOR; IMMUNOGLOBULIN G ANTIBODY; OVALBUMIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMORAL IMMUNITY; IMMUNIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, VIRAL; ATADENOVIRUS; DRUG CARRIERS; FOWLPOX VIRUS; GENETIC VECTORS; IMMUNIZATION, SECONDARY; MICE; MICE, INBRED C57BL; OVALBUMIN; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 78449245866     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00291-10     Document Type: Article

References (52)

1. Allan, R. S., C. M. Smith, G. T. Belz, A. L. van Lint, L. M. Wakim, W. R. Heath, and F. R. Carbone. 2003. Epidermal viral immunity induced by CD8alpha+ dendritic cells but not by Langerhans cells. Science 301:1925-1928.
2. Ba, L., C. E. Yi, L. Zhang, D. D. Ho, and Z. Chen. 2007. Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus. Appl. Microbiol. Biotechnol. 76:1131-1136.
3. Badovinac, V. P., J. S. Haring, and J. T. Harty. 2007. Initial T cell receptor transgenic cell precursor frequency dictates critical aspects of the CD8(-) T cell response to infection. Immunity 26:827-841.
4. Benko, M., and B. Harrach. 1998. A proposal for a new (third) genus within the family Adenoviridae. Arch. Virol. 143:829-837.
5. Beukema, E. L., M. P. Brown, and J. D. Hayball. 2006. The potential role of fowlpox virus in rational vaccine design. Expert Rev. Vaccines 5:565-577.
6. Both, G. W. 2009. Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment. Curr. Opin. Mol. Ther. 11:421-432.
7. Both, G. W., F. Cameron, A. Collins, L. J. Lockett, and J. Shaw. 2007. Production and release testing of ovine atadenovirus vectors. Methods Mol. Med. 130:69-90.
8. Boyle, D. B., M. A. Anderson, R. Amos, R. Voysey, and B. E. Coupar. 2004. Construction of recombinant fowlpox viruses carrying multiple vaccine antigens and immunomodulatory molecules. Biotechniques 37:104-111.
9. Boyle, D. B., A. D. Pye, R. Kocherhans, B. M. Adair, S. Vrati, and G. W. Both. 1994. Characterisation of Australian ovine adenovirus isolates. Vet. Microbiol. 41:281-291.
10. Bridgeman, A., Y. Roshorm, L. J. Lockett, Z. Z. Xu, R. Hopkins, J. Shaw, G. W. Both, and T. Hanke. 2009. Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine. Vaccine 28:474-483.
11. Buchbinder, S. P., D. V. Mehrotra, A. Duerr, D. W. Fitzgerald, R. Mogg, D. Li, P. B. Gilbert, J. R. Lama, M. Marmor, C. Del Rio, M. J. McElrath, D. R. Casimiro, K. M. Gottesdiener, J. A. Chodakewitz, L. Corey, and M. N. Robertson. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-1893.
12. Casimiro, D. R., A. J. Bett, T. M. Fu, M. E. Davies, A. Tang, K. A. Wilson, M. Chen, R. Long, T. McKelvey, M. Chastain, S. Gurunathan, J. Tartaglia, E. A. Emini, and J. Shiver. 2004. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J. Virol. 78:11434-11438.
13. Clarke, S. R., M. Barnden, C. Kurts, F. R. Carbone, J. F. Miller, and W. R. Heath. 2000. Characterization of the ovalbumin-specific TCR transgenic line OT-I: MHC elements for positive and negative selection. Immunol. Cell Biol. 78:110-117.
14. Dai, Y., E. M. Schwarz, D. Gu, W. W. Zhang, N. Sarvetnick, and I. M. Verma. 1995. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. U. S. A. 92:1401-1405.
15. den Haan, J. M., and M. J. Bevan. 2002. Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(-) and CD8(-) dendritic cells in vivo. J. Exp. Med. 196:817-827.
16. den Haan, J. M., S. M. Lehar, and M. J. Bevan. 2000. CD8(-) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192:1685-1696.
17. Diener, K. R., E. L. Lousberg, E. L. Beukema, A. Yu, P. M. Howley, M. P. Brown, and J. D. Hayball. 2008. Recombinant fowlpox virus elicits transient cytotoxic T cell responses due to suboptimal innate recognition and recruitment of T cell help. Vaccine 26:3566-3573.
18. Diener, K. R., L. M. Moldenhauer, A. B. Lyons, M. P. Brown, and J. D. Hayball. 2008. Human Flt-3 ligand-mobilized dendritic cells require additional activation to drive effective immune responses. Exp. Hematol. 36:51-60.
19. Dudziak, D., A. O. Kamphorst, G. F. Heidkamp, V. R. Buchholz, C. Trumpfheller, S. Yamazaki, C. Cheong, K. Liu, H. W. Lee, C. G. Park, R. M. Steinman, and M. C. Nussenzweig. 2007. Differential antigen processing by dendritic cell subsets in vivo. Science 315:107-111.
20. Emery, S., A. D. Kelleher, C. Workman, R. L. Puls, M. Bloch, D. Baker, J. Anderson, J. Hoy, S. Ip, K. Nalliah, L. D. Ward, M. G. Law, and D. A. Cooper. 2007. Influence of IFNgamma co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy. Hum. Vaccin. 3:260-267.
21. French, M. A., S. Tanaskovic, S. Fernandes, L. D. Ward, A. D. Kelleher, and S. Emery. 2010. Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a "high affinity" FcγRIIa genotype. AIDS 24:1983-1990.
22. Geiben-Lynn, R., J. R. Greenland, K. Frimpong-Boateng, and N. L. Letvin. 2008. Kinetics of recombinant adenovirus type 5, vaccinia virus, modified vaccinia ankara virus, and DNA antigen expression in vivo and the induction of memory T-lymphocyte responses. Clin. Vaccine Immunol. 15:691-696.
23. Greenough, T. C., C. K. Cunningham, P. Muresan, M. McManus, D. Persaud, T. Fenton, P. Barker, A. Gaur, D. Panicali, J. L. Sullivan, and K. Luzuriaga. 2008. Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Vaccine 26:6883-6893.
24. Gulley, J. L., P. M. Arlen, R. A. Madan, K. Y. Tsang, M. P. Pazdur, L. Skarupa, J. L. Jones, D. J. Poole, J. P. Higgins, J. W. Hodge, V. Cereda, M. Vergati, S. M. Steinberg, S. Halabi, E. Jones, C. Chen, H. Parnes, J. J. Wright, W. L. Dahut, and J. Schlom. 2010. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol. Immunother. 59:663-674.
25. Gulley, J. L., P. M. Arlen, K. Y. Tsang, J. Yokokawa, C. Palena, D. J. Poole, C. Remondo, V. Cereda, J. L. Jones, M. P. Pazdur, J. P. Higgins, J. W. Hodge, S. M. Steinberg, H. Kotz, W. L. Dahut, and J. Schlom. 2008. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin. Cancer Res. 14:3060-3069.
26. Hofmann, C., P. Loser, G. Cichon, W. Arnold, G. W. Both, and M. Strauss. 1999. Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo. J. Virol. 73:6930-6936. (Pubitemid 29327876)
27. Iyoda, T., S. Shimoyama, K. Liu, Y. Omatsu, Y. Akiyama, Y. Maeda, K. Takahara, R. M. Steinman, and K. Inaba. 2002. The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J. Exp. Med. 195:1289-1302.
28. Khatri, A., Z. Z. Xu, and G. W. Both. 1997. Gene expression by atypical recombinant ovine adenovirus vectors during abortive infection of human and animal cells in vitro. Virology 239:226-237.
29. Kumin, D., C. Hofmann, M. Rudolph, G. W. Both, and P. Loser. 2002. Biology of ovine adenovirus infection of nonpermissive cells. J. Virol. 76:10882-10893. (Pubitemid 35176205)
30. Lechleider, R. J., P. M. Arlen, K. Y. Tsang, S. M. Steinberg, J. Yokokawa, V. Cereda, K. Camphausen, J. Schlom, W. L. Dahut, and J. L. Gulley. 2008. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin. Cancer Res. 14:5284-5291.
31. Loser, P., C. Hofmann, G. W. Both, W. Uckert, and M. Hillgenberg. 2003. Construction, rescue, and characterization of vectors derived from ovine atadenovirus. J. Virol. 77:11941-11951.
32. Lousberg, E. L., C. K. Fraser, M. G. Tovey, K. R. Diener, and J. D. Hayball. 2010. Type I interferons mediate the innate cytokine response to recombinant fowlpox virus but not the induction of plasmacytoid-dependent adaptive immunity. J. Virol. 84:6549-6563.
33. Lyons, A. B., and C. R. Parish. 1994. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 171:131-137.
34. Paoletti, E. 1996. Applications of pox virus vectors to vaccination: an update. Proc. Natl. Acad. Sci. U. S. A. 93:11349-11353.
35. Pooley, J. L., W. R. Heath, and K. Shortman. 2001. Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells. J. Immunol. 166:5327-5330.
36. Rerks-Ngarm, S., P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, N. Premsri, C. Namwat, M. de Souza, E. Adams, M. Benenson, S. Gurunathan, J. Tartaglia, J. G. McNeil, D. P. Francis, D. Stablein, D. L. Birx, S. Chunsuttiwat, C. Khamboonruang, P. Thongcharoen, M. L. Robb, N. L. Michael, P. Kunasol, and J. H. Kim. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-2220.
37. Robert-Guroff, M. 2007. Replicating and non-replicating viral vectors for vaccine development. Curr. Opin. Biotechnol. 18:546-556.
38. Rosario, M., R. Hopkins, J. Fulkerson, N. Borthwick, M. F. Quigley, J. Joseph, D. C. Douek, H. Y. Greenaway, V. Venturi, E. Gostick, D. A. Price, G. W. Both, J. C. Sadoff, and T. Hanke. 2010. Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques. J. Virol. 84:5898-5908.
39. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, S. L. Topalian, R. M. Sherry, N. P. Restifo, J. R. Wunderlich, C. A. Seipp, L. Rogers-Freezer, K. E. Morton, S. A. Mavroukakis, L. Gritz, D. L. Panicali, and D. E. White. 2003. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin. Cancer Res. 9:2973-2980.
40. Santra, S., M. S. Seaman, L. Xu, D. H. Barouch, C. I. Lord, M. A. Lifton, D. A. Gorgone, K. R. Beaudry, K. Svehla, B. Welcher, B. K. Chakrabarti, Y. Huang, Z. Y. Yang, J. R. Mascola, G. J. Nabel, and N. L. Letvin. 2005. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J. Virol. 79:6516-6522.
41. Scheinecker, C., R. McHugh, E. M. Shevach, and R. N. Germain. 2002. Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J. Exp. Med. 196:1079-1090.
42. Schnorrer, P., G. M. Behrens, N. S. Wilson, J. L. Pooley, C. M. Smith, D. El-Sukkari, G. Davey, F. Kupresanin, M. Li, E. Maraskovsky, G. T. Belz, F. R. Carbone, K. Shortman, W. R. Heath, and J. A. Villadangos. 2006. The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proc. Natl. Acad. Sci. U. S. A. 103:10729-10734.
43. Sekaly, R. P. 2008. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J. Exp. Med. 205:7-12.
44. Shen, X., S. B. J. Wong, C. B. Buck, J. Zhang, and R. F. Siliciano. 2002. Direct priming and cross-priming contribute differentially to the induction of CD8+ CTL following exposure to vaccinia virus via different routes. J. Immunol. 169:4222-4229.
45. Smith, F. O., J. A. Klapper, J. R. Wunderlich, S. A. Rosenberg, and M. E. Dudley. 2009. Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma. J. Immunother. 32:870-874.
46. Swiecki, M., and M. Colonna. 2010. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol. Rev. 234:142-162.
47. Tatsis, N., J. C. Fitzgerald, A. Reyes-Sandoval, K. C. Harris-McCoy, S. E. Hensley, D. Zhou, S. W. Lin, A. Bian, Z. Q. Xiang, A. Iparraguirre, C. Lopez-Camacho, E. J. Wherry, and H. C. Ertl. 2007. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 110:1916-1923.
48. Taylor, J., and E. Paoletti. 1988. Fowlpox virus as a vector in non-avian species. Vaccine 6:466-467.
49. Wuest, T., G. W. Both, A. M. Prince, C. Hofmann, and P. Loser. 2004. Recombinant ovine atadenovirus induces a strong and sustained T cell response against the hepatitis C virus NS3 antigen in mice. Vaccine 22:2717-2721. (Pubitemid 38900646)
50. Yang, Y., H. C. Ertl, and J. M. Wilson. 1994. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1:433-442.
51. Yang, Y., K. Greenough, and J. M. Wilson. 1996. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther. 3:412-420.
52. Yang, Y., K. U. Jooss, Q. Su, H. C. Ertl, and J. M. Wilson. 1996. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 3:137-144.